BHVN
Biohaven Ltd
NYSE · Biotechnology
$11.60
+0.84 (+7.81%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 166.56M | 159.79M | 165.80M |
| Net Income | 26.40M | 27.52M | 28.79M |
| EPS | — | — | — |
| Profit Margin | 15.9% | 17.2% | 17.4% |
| Rev Growth | +0.5% | -2.4% | +23.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 483.78M | 445.82M | 505.70M |
| Total Equity | 780.22M | 946.94M | 927.70M |
| D/E Ratio | 0.62 | 0.47 | 0.55 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 53.49M | 47.96M | 56.14M |
| Free Cash Flow | 17.32M | 22.87M | 17.57M |